Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Very Bearish -75

Zoetis (ZTS) Stock Plummets 20% Following Disappointing Q1 Results and Guidance Cut

AI-generated analysis

πŸ“‰ Zoetis (ZTS) shares plunged 20% to $88.94 on Thursday, becoming the worst-performing stock in the S&P 500 for the day.

πŸ’Έ First-quarter earnings per share of $1.53 missed the Street forecast of $1.60 despite year-over-year growth.

πŸ“Š Reported sales of $2.26 billion fell short of analyst expectations around $2.3 billion.

πŸ“‰ The full-year 2026 EPS guidance was reduced to a range of $6.85–$7.00 from the prior $7.00–$7.10 projection.

πŸ›‘ Domestic sales declined approximately 8% year-over-year, with companion animal revenue dropping 11% due to weak consumer demand.

🌍 International operations grew 17% year-over-year to $1.1 billion, but included a non-recurring $100 million accounting timing benefit.

πŸ” Analysts from Stifel note that underlying operational performance is weaker than the headline numbers suggest after removing the one-time boost.

πŸ“‰ Chief Executive Kristin Peck attributed the downturn to rising consumer cost consciousness and a reduction in veterinary appointments.

πŸ› οΈ Management promised "decisive action" to sharpen commercial execution and continue disciplined cost management going forward.

⬇️ Full-year revenue guidance was trimmed to $9.68–$9.96 billion, missing Wall Street consensus estimates near $9.89 billion.

πŸ“‰ The stock's current price levels match lows not seen since early 2019.

πŸ“‰ Year-to-date losses for Zoetis have now reached 29%.

Bullish Signals
  • Zoetis adjusted earnings per share of $1.53 represented approximately 9% annual growth from the prior year's $1.48.
  • International operations delivered strong 17% year-over-year growth to reach $1.1 billion, supported by a 10% increase in companion animal product revenue.
  • The parasiticides product line contributed significantly to international expansion during the quarter.
  • Chief Executive Kristin Peck confirmed the company is implementing decisive action to sharpen commercial execution and continue to drive disciplined cost management.
  • Earnings beat year-over-year expectations despite missing analyst consensus by $0.07 per share.
Risk Factors
  • Zoetis shares plunged 20% to $88.94 on Thursday, marking the weakest performance among all S&P 500 constituents for the day.
  • First-quarter earnings of $1.53 per share missed the $1.60 Street forecast by $0.07, and sales of $2.26B trailed the $2.3B expectation.
  • Domestic sales declined approximately 8% year-over-year to $1.1 billion, driven by consumer reluctance to spend on pet care.
  • The companion animal category in the United States experienced an 11% drop due to weakening demand and intensified competitive dynamics.
  • Management warned of significant headwinds including rising consumer cost consciousness and a decline in veterinary appointments.
  • International growth of 17% included approximately $100 million in non-recurring revenue from a fiscal calendar adjustment, which masks weaker underlying performance.
  • The company reduced its full-year EPS outlook to $6.85–$7.00 from the previous range of $7.00–$7.10 due to challenging market conditions.
  • Full-year revenue projections were trimmed to a range of $9.68 billion to $9.96 billion, below the prior guidance of $9.825 billion to $10.025 billion.
  • The stock has suffered 29% losses year-to-date, trading at price levels not seen since early 2019.
Full Analysis
Zoetis Inc. (ZTS) shares experienced a significant selloff, plunging approximately 20% to close at $88.94 on Thursday, marking the weakest performance for any S&P 500 constituent that day and driving year-to-date losses to 29%. The sharp decline followed the company's first-quarter 2026 earnings report, which fell short of analyst expectations across key metrics. Reported quarterly earnings per share were $1.53, missing the Street consensus of $1.60, while sales reached $2.26 billion against a forecast of $2.3 billion. In response to the weaker-than-anticipated results, management cut its full-year 2026 EPS guidance range from $7.00-$7.10 to $6.85-$7.00 and revised revenue projections downward from $9.825-$10.025 billion to $9.68-$9.96 billion. Chief Executive Kristin Peck attributed the poor performance to challenging market conditions, specifically noting rising consumer cost consciousness that reduced veterinary appointments and dampened demand for higher-priced offerings. Domestic sales declined by approximately 8% year-over-year, with the U.S. companion animal category dropping 11% due to weakening demand and increased competition. Conversely, international operations grew 17% year-over-year to $1.1 billion, largely supported by a parasiticides product line and a 10% increase in companion animal product revenue. However, this international growth was partially inflated by a non-recurring $100 million timing benefit resulting from a fiscal calendar adjustment that accelerated revenue recognition; Stifel analyst Jonathan Block noted that after accounting for this one-time boost, core operational performance was materially weaker than initial headlines suggested. Looking ahead, Zoetis stated it is implementing "decisive action" to improve commercial execution, unlock revenue, and maintain disciplined cost management as consumer reluctance continues to press on the sector. The stock's valuation has dropped to levels last seen in early 2019 following Thursday's price action. Analysts from Stifel highlighted that underlying weakness, particularly in the pet care division, is more concerning than the headline numbers after adjusting for the one-time revenue acceleration. This marks a significant shift from Zoetis' previous reputation as a reliable growth story in the animal healthcare sector, with the company now facing heightened scrutiny on its domestic demand and future guidance execution.